Sign In
Buy IBD
$23.82
+0.0800 (+0.337%)
At Close: Jun 23, 2026
Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108
08:15am, Wednesday, 07'th Jan 2026
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste
Palisade Bio: Gut Prodrug For IBD With Catalysts
08:45pm, Monday, 22'nd Dec 2025
Palisade Bio's bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
07:21am, Wednesday, 03'rd Dec 2025
Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
Acuity Shines As It Transforms Itself. IBD's Stock Of The Day Nears Buy Point.
01:19pm, Monday, 01'st Dec 2025
Acuity is finding ways to make what seems like an ordinary business a growth and innovation vehicle, after expanding into a building-technology provider.
Inspire Corporate Bond ETF $IBD is Bare Financial Services Inc’s 8th Largest Position
03:26am, Monday, 01'st Dec 2025
Bare Financial Services Inc lifted its holdings in shares of Inspire Corporate Bond ETF (NYSEARCA:IBD) by 3.9% during the second quarter, according to its most recent disclosure with the SEC. The fund
Nu Holdings, IBD's Stock Of The Day And Latin America's Largest Fintech, Is Breakout Ready
01:29pm, Wednesday, 29'th Oct 2025
Nu Holdings, Latin America's largest financial technology company, is approaching a buy point after a messy, 40-week-long consolidation.
IBD's Stock Of The Day, One Of Newest S&P 500 Stocks, Tops Buy Point
02:30pm, Tuesday, 30'th Sep 2025
Interactive Brokers has become a major player in the industry. Its market cap of nearly $30 billion.
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
07:20am, Monday, 29'th Sep 2025
Launched on 07/10/2017, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund offering broad exposure to the Investment Grade Corporate Bond ETFs category of the market.
IBD and MarketWatch's sixth annual survey honors most trusted financial companies
06:00pm, Thursday, 25'th Sep 2025
Consumers want financial companies they can trust. Is your bank, broker or insurer on this most-trusted list?
AI, Tariffs In Spotlight With Earnings From Coreweave And China Stocks On Deck | IBD
09:49am, Friday, 08'th Aug 2025
IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Alibaba, CoreWeave and Atour Holdings. Check out our daily newsletter!
Stone secures IBD financing to offer credit to businesses in the Amazon
02:12pm, Monday, 04'th Aug 2025
Brazilian payments company Stone said on Monday it has secured 295 million reais ($53.4 million) in financing from the Inter-American Development Bank's private investment arm to expand credit offerin
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
07:21am, Tuesday, 29'th Jul 2025
The Inspire Corporate Bond ETF (IBD) was launched on 07/10/2017, and is a smart beta exchange traded fund designed to offer broad exposure to the Investment Grade Corporate Bond ETFs category of the m
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?
07:21am, Thursday, 29'th May 2025
Designed to provide broad exposure to the Investment Grade Corporate Bond ETFs category of the market, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund launched on 07/10/2017.
Nvidia Earnings: AI Titan Faces Key Questions On Production, China Exports | IBD
07:01am, Friday, 23'rd May 2025
IBD's Alexis Garcia and Ed Carson preview key upcoming earnings reports from Nutanix, Costco and Nvidia. Check out our daily newsletter!
-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion
